Waters Corporation reported first quarter 2026 revenue of $1.267 billion and adjusted EPS of $2.70, growing 20% year-over-year. These results reflect the first full quarter including the Biosciences and Diagnostic Solutions acquisition and exceeded analyst expectations.
Key Highlights
- Organic revenue grew 11% in constant currency, exceeding the high end of the company's guidance range by 200 basis points, led by strong instrument and chemistry sales.
- The newly acquired Biosciences and Diagnostic Solutions businesses contributed $520 million in revenue, outperforming the company's guidance by $40 million.
- Waters raised its full-year 2026 guidance, now expecting organic constant currency revenue growth of 6.5% to 8.0% and adjusted EPS of $14.40 to $14.60.